DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Oocyte Cryopreservation by Slow Freezing and Vitrification

Information source: Reproductive Medicine Associates of New Jersey
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Women Diagnosed With Cancer; Egg Donors; Single Women; Failed Sperm Procurement in IVF

Intervention: slow freeze (Procedure); Vitrification (Procedure)

Phase: Phase 2/Phase 3

Status: Terminated

Sponsored by: Reproductive Medicine Associates of New Jersey

Official(s) and/or principal investigator(s):
Richard T Scott, MD, HCLD, Study Director, Affiliation: RMA of NJ
Kathleen Ferry, BS, Study Chair, Affiliation: RMA of NJ


This study seeks to evaluate whether the vitrification technique, as compared to the more traditional slow-cooling technique, leads to higher rates of successful thawing, fertilization, implantation and delivery.

Clinical Details

Official title: Longitudinal Evaluation of Vitrification of Human Oocytes

Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Oocytes survival after thaw

Secondary outcome:



Detailed description: Cryopreservation (freezing) of human gametes (unfertilized egg) provides a great potential to preserve or extend fertility in the face of disease and social circumstances (cancer diagnosis, delaying childbirth, single women, etc.). There are two methods for storage of oocytes (unfertilized eggs): slow freezing or vitrification (uses higher concentrations of cryoprotectant and faster cooling rates). Slow freezing is the standard method and has been successful for embryos since 1983 and more recently for oocytes. Recent reports indicate that vitrification may be more successful than slow freezing. The aim of this study is to examine the rate at which frozen eggs survive freezing and thawing, the rate at which the frozen/thawed eggs fertilize with sperm and the pregnancy outcomes of oocyte (egg) vitrification cycles to determine whether the outcomes are similar or better than standard oocyte (egg) cryopreservation (freezing) cycles.


Minimum age: 21 Years. Maximum age: 50 Years. Gender(s): Female.


Inclusion Criteria:

- Age between 21 and 50 years, at the time of informed consent.

- Subjects must agree to undergo intracytoplasmic sperm injection (ICSI)

Exclusion Criteria:

- Presence of any medical condition that contraindicates ovarian stimulation, in vitro

fertilization or pregnancy.

Locations and Contacts

Additional Information

Reproductive Medicine Associates of New Jersey

Starting date: July 2009
Last updated: November 18, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017